Prostate Cancer: Basic Research & Pathophysiology IMP29-03 MTOR EXPRESSION IN PROSTATE CANCER AND IMPLICATIONS AS PROGNOSTIC ROLE WITH META-ANALYSIS OF THE LITERATURE
Section snippets
INTRODUCTION AND OBJECTIVES
The mammalian target of rapamycin (mTOR) pathway is known to play an important role in oncology. However, its role in prostate cancer (PCa) has not been fully understood. The aim of the study was to evaluate the expression of mTOR, phosphorylated-mTOR (p-mTOR) and Eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) in patients with PCa using tissue microarray (TMA) technique and to assess their correlation with clinico-pathological parameters and outcome.
METHODS
Tissue samples from 115 consecutive patients who underwent radical prostatectomy were constructed to a TMA. In every case four localisations were included: A) from the tumour center, B) malignant border of the tumour, C) tumour adjacent benign tissue and D) tumour-distant benign prostatic tissue. Expression scores were strati ed according to their respective median immune reactive score 0-12 into ‘weak’ (< median) and ‘strong’ (= median). A meta-analysis of studies from Medline, Scopus and Web
RESULTS
Expression scores of mTOR, in A, B, C and D were 9.1, 8.8, 5.0 and 6.8 (p<0.01), p-mTOR scores were 7.4, 7.2, 2.0, 4.6 (p<0.01) while 4E-BP1 scores were 8.0, 7.6, 2.6 and 3.1 (p<0.01), respectively. We observed lower p-mTOR scores in A samples (6.3 and 7.9; p=0.01) in locally advanced vs. organ con ned PCa. Overall, 523 studies were identi ed from the databases and relevant references and 4 studies were added to our cohort for the meta-analysis. We found that ‘strong’ staining of p-mTOR was
CONCLUSIONS
All 3 markers showed local gradients of expression in PCa tissue. Moreover, expression characteristics suggest disorders in the mTOR system. In particular p-mTOR was associated with more aggressive PCa and could be clinically useful as a prognostic marker for BCR and to assess their local diversity as well as their correlation with clinico- pathological parameters.
References (0)
Cited by (0)
Source of Funding: None